Table I.
Association between B7-H3 or CD163+ TAMs and clinicopathological features in 134 patients with UCB.
| B7-H3 expression | CD163+ TAM infiltration | ||||||
|---|---|---|---|---|---|---|---|
| Feature | Patients, n% | Low, n (%) | High, n (%) | P-value | Low, n (%) | High, n (%) | P-value |
| Age, years | 0.067 | 0.634 | |||||
| <65 | 53 (39.6) | 21 (51.2) | 32 (34.4) | 31 (41.3) | 22 (37.3) | ||
| ≥65 | 81 (60.4) | 20 (48.8) | 61 (65.6) | 44 (58.7) | 37 (62.7) | ||
| Gender | 0.330 | 0.855 | |||||
| Male | 115 (85.8) | 37 (90.2) | 78 (83.9) | 64 (85.3) | 51 (86.4) | ||
| Female | 19 (14.2) | 4 (9.8) | 15 (16.1) | 11 (14.7) | 8 (13.6) | ||
| Tumor stage | 0.202 | 0.220 | |||||
| Ta/CIS/T1 | 19 (14.1) | 8 (19.5) | 11 (11.8) | 12 (16.0) | 7 (11.9) | ||
| T2 | 58 (43.3) | 21 (51.2) | 37 (39.8) | 36 (48.0) | 22 (37.3) | ||
| T3 | 40 (29.9) | 9 (22.0) | 31 (33.3) | 21 (28.0) | 19 (32.2) | ||
| T4 | 17 (12.7) | 3 (7.3) | 14 (15.1) | 6 (8.0) | 11 (18.6) | ||
| Tumor grade | 0.201 | 0.177 | |||||
| Low | 27 (20.1) | 11 (26.8) | 16 (17.2) | 12 (16.0) | 15 (25.4) | ||
| High | 107 (79.9) | 30 (73.2) | 77 (82.8) | 63 (84.0) | 44 (74.6) | ||
| Lymph node metastasis | 0.185 | 0.364 | |||||
| Yes | 40 (29.9) | 9 (22.0) | 31 (33.3) | 20 (26.7) | 20 (33.9) | ||
| No | 94 (70.1) | 32 (78.0) | 62 (66.7) | 55 (73.3) | 39 (66.1) | ||
| Recurrence | 0.306 | 0.192 | |||||
| Yes | 71 (53.0) | 19 (46.3) | 52 (55.9) | 36 (48.0) | 35 (59.3) | ||
| No | 63 (47.0) | 22 (53.7) | 41 (44.1) | 39 (52.0) | 24 (40.7) | ||
| Distant metastasis | 0.015 | 0.038 | |||||
| Yes | 57 (42.5) | 11 (26.8) | 46 (49.5) | 26 (34.7) | 31 (52.5) | ||
| No | 77 (57.5) | 30 (73.2) | 47 (50.5) | 49 (65.3) | 28 (47.5) | ||
| Vascular invasion | 0.009 | 0.012 | |||||
| Yes | 84 (62.7) | 19 (46.3) | 65 (69.9) | 40 (53.3) | 44 (74.6) | ||
| No | 50 (37.3) | 22 (53.7) | 28 (30.1) | 35 (46.7) | 15 (25.4) | ||
CD, cluster of differentiation; TAM, tumor-associated macrophage.